Bioxan® Tocotrienols
More information
Advanced Vitamin E Innovation for Visible Skin Performance
While tocopherols are widely used in cosmetic formulations, tocotrienols represent the most biologically potent members of the Vitamin E family. Thanks to their unsaturated isoprenoid side chain, tocotrienols exhibit superior membrane mobility, optimized antioxidant distribution, and broader biological activity.
Bioxan® Tocotrienols deliver a next-generation, multi-target dermocosmetic solution, clinically evaluated under dermatological control with robust statistical analysis.
Clinically Demonstrated
In Vitro Performance
The anti-inflammatory activity of Bioxan® Tocotrienols (1%) was assessed in stimulated human keratinocytes by measuring pro-inflammatory cytokine production.
Experimental Design
Keratinocytes (100% confluent) were cultured in DMEM + 10% FBS.
- Negative Control (NCM): non-stimulated cells
- Inflammation Control (IC): cells stimulated with Invitools™ inflammatory agent
Cells were exposed to the inflammatory stimulus ± tocotrienols (1%) for 1.5 h, followed by overnight incubation (≥ triplicates).
Analysis
- Cytokines: IL-1β, IL-6, IL-8 (immunoassay, 450 nm), normalized to viable cells
- Cell viability: MTT assay (570 nm)
Results
Bioxan® Tocotrienols significantly reduced IL-1β, IL-6, and IL-8 levels in stimulated keratinocytes without affecting cell viability, confirming anti-inflammatory activity independent of cytotoxic effects.
In Vivo Performance
56-Day Dermatological Study (n = 22)
Study Design Overview
- Open-label, single-arm clinical study
- 22 female subjects (47–62 years)
- Twice-daily facial application
- Duration: 56 days
- Evaluation time points: D0 (baseline), D28, D56
- Significance level: p < 0.05 (95% confidence interval)
- All measurements performed under standardized environmental conditions
The study evaluated five major skin parameters:
- Hyperpigmentation
- Fine lines
- Elasticity
- Erythema (redness)
- Glycation (AGEs accumulation)
1. Depigmenting Effect – Targeted Dark Spot Reduction
Methodology
- Instrument: Mexameter® MX18
- Parameter: Melanin Index
- Measurements performed:
- Directly on hyperpigmented spot
- On adjacent normal skin (reference area)
- Three consecutive measurements per site
Statistical Analysis
- Spot vs adjacent skin: Wilcoxon signed-rank test (paired, non-parametric)
- Time-point comparisons (D28, D56 vs baseline):
- Linear Mixed-Effects Model (LMM) when normality was met
- Wilcoxon test when assumptions were not met
- Significance threshold: p < 0.05
Results
- At baseline: Dark spots showed 38% higher melanin levels vs surrounding skin (p < 0.05)
- Day 28: 19% reduction in spot melanin
- Day 56: 21% reduction in spot melanin
- Contrast reduced from 38% to 21% (p < 0.05)
- Surrounding skin reduced only 9%, confirming a targeted depigmenting effect
Conclusion: Significant and selective reduction of hyperpigmentation after 56 days.
2. Anti-Glycation Effect – Reduction of AGE Accumulation
Methodology
- Instrument: AGE Reader mu
- Parameter: Skin autofluorescence (quantification of Advanced Glycation End-products)
- Three consecutive measurements per zone
Statistical Analysis
- Continuous variable
- Linear Mixed-Effects Model (LMM)
- Significance set at p < 0.05
Results
- After 56 days: 6% reduction in AGEs vs baseline
Conclusion: Demonstrated protective effect against glycation-related aging mechanisms.
3. Anti-Erythema Effect – Visible Redness Reduction
Methodology
- Instrument: Mexameter® MX18
- Parameter: Hemoglobin Index
- Randomized cheek area
- Three consecutive measurements averaged
Statistical Analysis
- Continuous variable
- Linear Mixed-Effects Model (LMM)
- D28 and D56 compared vs baseline
- p < 0.05
Results
- Day 28: 9% reduction in hemoglobin index
- Day 56: 8% reduction vs baseline
Conclusion: Clinically proven soothing and anti-redness efficacy.
4. Elasticity Improvement – Enhanced Viscoelastic Balance
Methodology
- Instrument: Cutometer® Dual MPA 580
- Parameter: R6 (Uv/Ue ratio)
- Lower R6 values indicate improved elasticity
Statistical Analysis
- Continuous variable
- Linear Mixed-Effects Model (LMM)
- Significant reductions at D28 and D56 (p < 0.05)
Results
- Day 28: 31% decrease in R6
- Day 56: 31% decrease vs baseline
Conclusion: Strong improvement in skin elasticity and biomechanical resilience.
5. Reduction of Fine Lines
Methodology
- Clinical evaluation using a 10-point ordinal photo-clinical grading scale (0–9)
- Standardized photography conditions
- Lower score = fewer visible fine lines
Statistical Analysis
- Ordinal variable
- Cumulative Link Mixed Model (CLMM)
- Comparison: D28 and D56 vs baseline
- Significance: p < 0.05
- Median considered most robust descriptor
Results
- After 56 days:
- 20% median reduction in global fine lines score
- Statistically significant (p < 0.05)
Conclusion: Clinically validated wrinkle-reducing efficacy.
Bioxan® Tocotrienols
Scientifically Substantiated Multi-Target Performance
Bioxan® Tocotrienols demonstrated:
- Dark spot reduction (21%)
- Fine line reduction (20%)
- Elasticity improvement (31%)
- Redness reduction (8–9%)
- Anti-glycation protection (6%)
A High-Value Active for Next-Generation Dermocosmetics
Bioxan® Tocotrienols provide a scientifically validated, multifunctional approach to:
- Anti-aging formulations
- Brightening treatments
- Sensitive skin care
- Urban pollution defense
- Dermocosmetic repair
Backed by instrumental measurements, appropriate statistical modeling, and dermatological supervision, this ingredient offers measurable biological performance translated into visible clinical outcomes.
More information
